loncastuximab tesirine
Selected indexed studies
- Loncastuximab Tesirine. (, 2006) [PMID:34014627]
- Loncastuximab Tesirine: First Approval. (Drugs, 2021) [PMID:34143407]
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. (Lancet Oncol, 2021) [PMID:33989558]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Loncastuximab Tesirine. (2006) pubmed
- Loncastuximab Tesirine: First Approval. (2021) pubmed
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. (2021) pubmed
- Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. (2024) pubmed
- Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial. (2025) pubmed
- Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma. (2022) pubmed
- Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (2024) pubmed
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. (2022) pubmed
- Loncastuximab Tesirine-lpyl. (2021) pubmed
- Loncastuximab tesirine: Risk for dose variance. (2024) pubmed